Amazing prediction when you consider that the HIV trial results essentially failed to deliver the goods - unchanged result from the previous trial.
One actually wonders why BIT ran a second phase 2 trial when BIT225 was basically unchanged.
C14 has a job ahead of it being able to convince a third party that BIT225 has anything to offer in the biotech sector other than a potential assistant with another ant-viral drug.
BIT Price at posting:
0.3¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)